The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study;Virkningen af losartan versus atenolol på kardiovaskulær morbiditet og mortalitet hos patienter med hypertension og ekg-verificeret venstre ventrikelhypertrofi i LIFE-undersøgelsen

Ugeskrift for Laeger

Volumn 165, Issue 5, 2003, Pages 456-459

  Ibsen, Hans ^a   Pedersen, Ole Lederballe ^b   Dahlöf, Björn ^b   Kjeldsen, Sverre E ^b   Lindholm, Lars H ^b  

^a Medicinsk Afdeling M   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LOSARTAN;

ADULT; AGED; ANGIONEUROTIC EDEMA; ANKLE EDEMA; ARTICLE; BLOOD PRESSURE REGULATION; BRADYCARDIA; CANCER; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; DYSPNEA; ELECTROCARDIOGRAM; ESSENTIAL HYPERTENSION; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SIDE EFFECT; STROKE; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0037467917     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955-64.
2. Dahlöf B, Devereux RB, de Faire U et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods. Am J Hypertens 1997; 10: 705-13.
3. Dahlöf B, Devereux RB, Kjeldsen SS et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
4. Mathew J, Sleight P, Lonn E et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104: 1615-21.
5. Brunner HR. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 2001; 87: 3-9C.
6. Timmermann PB. Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens Res 1999; 22: 147-53.
7. Dahlöf B, Devereux RB, Julius S et al. Characteristics of 9,194 patients with left ventricular hypertrophy: the LIFE Study. Hypertension 1998; 32: 989-97.
8. Okin PM, Roman MJ, Devereux RB et al. Electrocardiographic identification of increased left ventricular mass by simple voltage- duration products. J Am Coll Cardiol 1995; 25: 417-23.
9. Andersson KM, Wilson PWF, Odell PM et al. An updated coronary risk profile: a statement for health professionals. Circulation 1991; 83: 356-62.
10. Kjeldsen SE, Julius S, Hedner T et al. Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomised intervention trials. Blood Pressure 2001; 10: 190-2.
11. Verdecchia P, Porcellati C, Reboldi G et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104: 2039-44.
12. Hansson L, Lindholm LH, Niskamen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.